What to say and how to say it: Effective communication for cardiovascular disease prevention

Current Opinion in Cardiology

Volumn 31, Issue 5, 2016, Pages 537-544

  Navar, Ann Marie ^a   Stone, Neil J ^b   Martin, Seth S ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

prevention; risk communication; shared decision making

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; PATIENT AUTONOMY; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SELF CONCEPT; CLINICAL DECISION MAKING; DECISION MAKING; DOCTOR PATIENT RELATION; ETHICS; EVIDENCE BASED MEDICINE; INTERPERSONAL COMMUNICATION; PATIENT PARTICIPATION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; UNCERTAINTY;

CARDIOVASCULAR DISEASES; CLINICAL DECISION-MAKING; COMMUNICATION; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; UNCERTAINTY;

EID: 84978681139     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000322     Document Type: Review

References (27)

1. Alston C, Paget L, Halvorson G, et al. Communicating with patients on healthcare evidence. Discussion Paper.Washington, DC: Institute of Medicine; 2012; http: //nam.edu/wp-content/uploads/2015/06/VSRT-Evidence.pdf
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-2934.
3. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 2015; 65: 1361-1368.
4. Samsa GP, Cohen SJ, Goldstein LB, et al. Knowledge of risk among patients at increased risk for stroke. Stroke 1997; 28: 916-921.
5. van derWeijden T, van Steenkiste B, Stoffers HE, et al. Primary prevention of cardiovascular diseases in general practice: mismatch between cardiovascular risk, and patients' risk perceptions. Med Decis Making 2007; 27: 754-761.
6. Frijling BD, Lobo CM, Keus IM, et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educ Couns 2004; 52: 47-53.
7. Koelewijn-van Loon MS, van der Weijden T, Ronda G, et al. Improving lifestyle, and risk perception through patient involvement in nurse-led cardiovascular risk management: a cluster-randomized controlled trial in primary care. Prev Med 2010; 50: 35-44.
8. Edwards A, Thomas R, Williams R, et al. Presenting risk information to people with diabetes: evaluating effects, and preferences for different formats by a web-based randomised controlled trial. Patient Educ Couns 2006; 63: 336-349.
9. Krones T, Keller H, Sonnichsen A, et al. Absolute cardiovascular disease risk, and shared decision making in primary care: a randomized controlled trial. Ann Fam Med 2008; 6: 218-227.
10. Goodyear-Smith F, Arroll B, Chan L, et al. Patients prefer pictures to numbers to express cardiovascular benefit from treatment. Ann Fam Med 2008; 6: 213-217.
11. Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: a systematic review. Ann Intern Med 2014; 161: 270-280.
12. McCaul KD, Branstetter AD, Schroeder DM, Glasgow RE. What is the relationship between breast cancer risk, and mammography screening?. A meta-Analytic review. Health Psychol 1996; 15: 423-429.
13. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003; 290: 953-958.
14. SPRINT ResearchGroup. Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-2116.
15. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S49-S73.
16. Yamagishi K. When a 12.86% mortality is more dangerous than 24.14%: implications for risk communication. App Cog Psych 1999; 11: 12.
17. Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997; 127: 966-972.
18. Soureti A, Hurling R, Murray P, et al. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil 2010; 17: 519-523.
19. Frileux S, Munoz Sastre MT, Mullet E, Sorum PC. The impact of the preventive medical message on intention to change behavior. Patient Educ Couns 2004; 52: 79-88.
20. Goldman RE, Parker DR, Eaton CB, et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006; 4: 205-212.
21. Fair AK, Murray PG, Thomas A, Cobain MR. Using hypothetical data to assess the effect of numerical format, and context on the perception of coronary heart disease risk. Am J Health Promot 2008; 22: 291-296.
22. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), and the European Atherosclerosis Society (EAS). Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (Suppl 1): S1-S44.
23. Lipkus IM. Numeric, verbal, and visual formats of conveying health risks: suggested best practices, and future recommendations. Med Decis Making 2007; 27: 696-713.
24. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2021-2031.
25. Ford I, Murray H, McCowan C, Packard CJ. Long-Term safety, and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation 2016; 133: 1073-1080.
26. Eckel RH, Jakicic JM, Ard JD, et al. 2013AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2960-2984.
27. Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014; 1: CD001431.